HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
HER2-deregulated non-small cell lung cancer is an orphan of any specific therapy, probably because of lack of both accurate patient selection and effective drugs. Recent evidence suggests that osimertinib could be effective in HER2-amplified or mutated lung cancer as a single agent or in combination. Clin Cancer Res; 24(11); 2470-2. ©2018 AACRSee related article by Liu et al., p. 2594.